Category: Licensing/Collaboration Deal Region: Europe · United Kingdom Company: Glaxosmithkline Uk Ltd

GSK announces $1.25 bn settlement between ViiV Healthcare & Gilead on patents relating to dolutegravir

GSK announces $1.25 bn settlement between ViiV Healthcare & Gilead on patents relating to dolutegravir
GlaxoSmithKline plc (GSK) announced that ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi & Co. Limited (Shionogi) as shareholders, has agreed to settle the global patent infringement litigation between GSK, Shionogi and Gilead Sciences, Inc. (Gilead) concerning ViiV Healthcare

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!